stockportfolio.pro
Alamar Biosciences, Inc. (ALMR)
Healthcare · Medical Devices · NasdaqGS
Alamar Biosciences, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $25.14M | $74.21M |
| Gross profit | $8.61M | $41.70M |
| Net income | $-47.07M | $-29.82M |
| Net margin | -187.2% | -40.2% |
Source: Alamar Biosciences, Inc. SEC filings (10-K).
Explore 2 years of Alamar Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALMR in your portfolio →
Alamar Biosciences, Inc. financial history by metric
About Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.
Alamar Biosciences, Inc. — frequently asked questions
What is Alamar Biosciences, Inc.'s revenue?
Alamar Biosciences, Inc. (ALMR) reported revenue of $74.21M for fiscal year 2025, up 195.2% from the prior year, according to its SEC filings.
Is Alamar Biosciences, Inc. profitable?
No — ALMR reported a net loss of $-29.82M in fiscal 2025.
What is ALMR's P/E ratio?
Alamar Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Alamar Biosciences, Inc. have?
As of fiscal year 2025, ALMR carried roughly $9.81M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Alamar Biosciences, Inc.'s gross margin?
ALMR's gross margin was 56.2% in fiscal 2025 — gross profit of $41.70M on revenue of $74.21M.
What is Alamar Biosciences, Inc.'s market cap?
Alamar Biosciences, Inc. (ALMR) has a market capitalization of about $1.51B, based on the latest data in our nightly-refreshed cache.
When does Alamar Biosciences, Inc.'s fiscal year end?
ALMR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Alamar Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.